Hematological response to first-line treatment by treatment group
| . | ELTR + IST (n = 49), n (%) . | IST (n = 49), n (%) . | Difference in % (95% CI)∗ . | P value . |
|---|---|---|---|---|
| 4 mo | ||||
| OR | 32 (65) | 26 (53) | 12 (−7 to 32) | .218 |
| CR | 15 (31) | 6 (12) | 18 (3 to 34) | .027 |
| PR | 17 (35) | 20 (41) | — | — |
| NR | 16 (33) | 23 (47) | −14 (−33 to 5) | .149 |
| Death | 1 (2) | 0 (0) | — | — |
| 6 mo | ||||
| OR | 27 (55) | 25 (51) | 4 (−16 to 24) | .686 |
| CR | 17 (35) | 9 (18) | 16 (−1 to 34) | .067 |
| PR | 10 (20) | 16 (33) | — | — |
| Relapse | 5 (10) | 1 (2) | — | — |
| NR | 16 (33) | 22 (45) | — | — |
| Second-line therapy | 12 (24) | 14 (29) | — | — |
| HSCT | 2 (4) | 2 (4) | — | — |
| Death | 1 (2) | 1 (2) | — | — |
| 1 y | ||||
| OR | 25 (51) | 22 (45) | 6 (−14 to 26) | .544 |
| CR | 16 (33) | 16 (33) | 0 (−19 to 19) | 1.0 |
| PR | 9 (18) | 6 (12) | — | — |
| Relapse | 7 (14) | 4 (8) | — | — |
| NR | 14 (29) | 21 (43) | — | — |
| Second-line therapy | 8 (16) | 14 (29) | — | — |
| HSCT | 2 (4) | 3 (6) | — | — |
| Second-line therapy + HSCT | 4 (8) | 4 (8) | — | — |
| Death | 1 (2) | 1 (2) | — | — |
| Not reached | 2 (4) | 1 (2) | — | — |
| . | ELTR + IST (n = 49), n (%) . | IST (n = 49), n (%) . | Difference in % (95% CI)∗ . | P value . |
|---|---|---|---|---|
| 4 mo | ||||
| OR | 32 (65) | 26 (53) | 12 (−7 to 32) | .218 |
| CR | 15 (31) | 6 (12) | 18 (3 to 34) | .027 |
| PR | 17 (35) | 20 (41) | — | — |
| NR | 16 (33) | 23 (47) | −14 (−33 to 5) | .149 |
| Death | 1 (2) | 0 (0) | — | — |
| 6 mo | ||||
| OR | 27 (55) | 25 (51) | 4 (−16 to 24) | .686 |
| CR | 17 (35) | 9 (18) | 16 (−1 to 34) | .067 |
| PR | 10 (20) | 16 (33) | — | — |
| Relapse | 5 (10) | 1 (2) | — | — |
| NR | 16 (33) | 22 (45) | — | — |
| Second-line therapy | 12 (24) | 14 (29) | — | — |
| HSCT | 2 (4) | 2 (4) | — | — |
| Death | 1 (2) | 1 (2) | — | — |
| 1 y | ||||
| OR | 25 (51) | 22 (45) | 6 (−14 to 26) | .544 |
| CR | 16 (33) | 16 (33) | 0 (−19 to 19) | 1.0 |
| PR | 9 (18) | 6 (12) | — | — |
| Relapse | 7 (14) | 4 (8) | — | — |
| NR | 14 (29) | 21 (43) | — | — |
| Second-line therapy | 8 (16) | 14 (29) | — | — |
| HSCT | 2 (4) | 3 (6) | — | — |
| Second-line therapy + HSCT | 4 (8) | 4 (8) | — | — |
| Death | 1 (2) | 1 (2) | — | — |
| Not reached | 2 (4) | 1 (2) | — | — |
NR, no response; CI, confidence interval.